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Abstract
Background Socioeconomic status (SES) has been associated with early mortality in cancer patients. However, the association
between SES and outcome in colorectal cancer patients is largely unknown. The aim of this study was to investigate whether SES
is associated with short- and long-term outcome in patients undergoing curative surgery for colorectal cancer.
Methods Patients who underwent curative surgery in the region of Rotterdam for stage I–III colorectal cancer between January
2007 and July 2014 were included. Gross household income and survival status were obtained from a national registry provided
by Statistics Netherlands Centraal Bureau voor de Statistiek. Patients were assigned percentiles according to the national income
distribution. Logistic regression and Cox proportional hazard regression were performed to assess the association of SESwith 30-
day postoperative complications, overall survival and cancer-specific survival, adjusted for known prognosticators.
Results For 965 of the 975 eligible patients (99%), gross household income could be retrieved. Patients with a lower SES more
often had diabetes, more often underwent an open surgical procedure, and had more comorbidities. In addition, patients with a
lower SES were less likely to receive (neo) adjuvant treatment. Lower SES was independently associated with an increased risk
of postoperative complications (Odds ratio per percent increase 0.99, 95%CI 0.99–0.998, p = 0.004) and lower cancer-specific
mortality (Hazard ratio per percent increase 0.99, 95%CI 0.98–0.99, p = 0.009).
Conclusion This study shows that lower SES is associated with increased risk of postoperative complications, and poor cancer-
specific survival in patients undergoing surgery for stage I–III colorectal cancer after correcting for known prognosticators.
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Introduction
With an incidence of 464,800 patients in 2012, colorectal
cancer (CRC) is the second most common cancer in Europe
and constitutes a large burden, both in economic and in med-
ical terms.[1, 2] In a recent European article, average costs for
treating a single patient with colorectal cancer were estimated
at 40,000 Euros [2]. Currently, the TNM classification is the
most important determinant for treatment decisions and out-
come. Resection still remains the only cure, and the 5-year
survival rate for patients with stage I–III varies between 53
and 92% [1]. Still, there are individual differences in clinical
outcome within a single tumour stage [3]. Next to these tu-
mour characteristics, several patient factors such as obesity,
diabetes mellitus, smoking and nutritional status have been
investigated and associated with survival, yet much of the
disparity in prognosis remains unexplained [4–7].
A possible explanation for differences in survival is socio-
economic status (SES). Not only does this influence the ability
to pay medical bills and having financial resources to follow
through with all hospital check-ups but also other correlating
factors such as obesity and diabetes may also have an influ-
ence on post-resection CRC survival [8–10]. In previous
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studies, SES has been investigated as a possible prognostic
factor for survival in cancer patients with contradicting results
[11–23]. Some of this variability in outcomes may be ex-
plained by accessibility of healthcare [22, 23]. Some studies
have been performed in countries where access to and the
quality of healthcare is directly linked to income (e.g. USA)
[22, 23], whereas others were conducted in countries with
equal healthcare access (e.g. Great Britain and Scandinavia)
[11–23]. The Dutch healthcare system is known for its equal
healthcare access,[24, 25] meaning that differences in out-
come associated with SES can be attributed to patient and
provider factors and their interaction, rather than disparities
in healthcare [26]. In the current study, we aimed to explore
the association between SES, as assessed by household in-
come, and outcomes following curative resection for stage
I–III colorectal cancer in the Netherlands.
Methods
Study Population
Patients with stage I–III colorectal cancer who underwent cu-
rative surgery, enrolled in the MATCH-study between 2007
and 2014, were included in this study. The MATCH study is a
prospective multicentre cohort study including patients to ob-
tain fresh frozen CRC tissue samples with matched clinical
data from 2007 until December 2017 in six hospitals in the
region of Rotterdam [27].
The rationale of the MATCH study was to identify sub-
types of colorectal cancer, related prognostic markers and out-
come of treatment [28]. The study was approved by the
Erasmus MC IRB (MEC-2007-088) and all patients provided
written informed consent.
Study Parameters
Socioeconomic status was defined as gross household income
(GHI), the most commonly used and accepted surrogate mark-
er for SES [26, 29–31]. GHI from the year prior to surgery was
used for analyses, as the income in the year of surgery was
possibly lower due to disease-related absence from work.
Annual earnings were obtained from Statistics Netherlands,
a governmental organisation enabling studies on social issues
on the basis of reliable statistical information (Centraal Bureau
voor de Statistiek; CBS), including all types of income of
people sharing a household or place of residence combined
(i.e. salary, state pension, social compensation, and investment
revenues). Patients were assigned percentiles and quartiles
(Q1–Q4) according to the national income distribution (i.e.
patients of a household with an annual salary corresponding
to 0–25% of the GHI of the Dutch population were stratified
to the first income quartile). Baseline characteristics and
variables were retrieved from the prospective database of the
MATCH study.
Dutch Healthcare System
The current Dutch healthcare system was introduced on
January 1, 2006. All Dutch citizens are legally required to
have healthcare insurance offered by several private insurers.
Basic insurance premiums have a legal maximum and allow-
ances are available for the lower incomes. Basic insurances
cover all medical costs concerning regular cancer care includ-
ing all in hospital care, costs for medicines, cancer rehabilita-
tion, emergency transfer to hospitals, dietary help and psycho-
social assistance. Out-of-pocket expenses such as transporta-
tion represented 14.7 percent of healthcare spending in 2014
[32].
Outcome Measures
The primary endpoints were overall survival (OS) and cancer-
specific survival (CSS) after surgery for colorectal cancer,
calculated from the day of surgery to the day of death (from
disease) or loss to follow-up, whichever came first. Date and
cause of death were obtained from the national registry of
Statistics Netherlands. Secondary outcome measures were
30-day postoperative complications. Severity of complica-
tions was scored according to the Clavien-Dindo classifica-
tion, and major 30-day postoperative complications were de-
fined as Clavien-Dindo score ≥ 3a [33].
Statistical Methods
Descriptive statistics and multivariable analyses were per-
formed using SPSS version 24.0 (SPSS, Inc., Chicago, IL,
USA). Differences in baseline characteristics between the
SES quartiles were tested with Pearson’s chi-square analysis
or Mann-Whitney U-test as appropriate. Logistic regression
analysis was used to calculate the odds ratio (OR) with 95%
confidence intervals (95% CI) to evaluate the influence of
SES, patient and tumour characteristics and operation tech-
niques on 30-day postoperative complications. The outcomes
OS and CSS were analysed with Cox proportional hazards
regression. Unadjusted differences in the survival between
income quartiles were assessed using the log-rank test. The
predictors included in regression models were selected based
on clinical relevance based on previous literature. Two-sided
p values < 0.05 were considered statistically significant.
Results
A total of 975 patients met the inclusion criteria. For 10 pa-
tients, gross household income (GHI) could not be retrieved,
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leaving a final sample size of 965 (99%) patients. Patients with
low SES were more often female and older (both p < 0.001)
(Table 1). Diabetes mellitus and higher American Society of
Anesthesiologists (ASA) classification were more common
among patients with low SES (both p = 0.001). The
Charlson comorbidity index was significantly higher for pa-
tients in the lowest quartile (p < 0.001). The median length of
stay (LOS) was higher for patients in the lowest quartile (p <
Table 1 Baseline characteristics
Q1 % Q2 % Q3 % Q4 % p value
(n = 244) (n = 348) (n = 187) (n = 186)
Demographics
Sex female 146 (59.8) 153 (44) 75 (40.1) 63 (33.9) < 0.001
Age (median, IQR) 76 (69–81) 72 (66–78) 66 (60–72) 59 (55–65) < 0.001
BMI (median, IQR) 25.9 (23.3–29.4) 25.9 (23.5–28.5) 25.8 (23.0–28.3) 25.4 (23.4–28.7) 0.795
CEA preoperative (median, IQR) 3.3 (2.0–8.0) 3.5 (2.0–8.0) 3.3 (1.85–6.9) 2.9 (1.9–5.75) 0.160
Comorbid conditions
Charlson comorbidity
index (median, IQR)
1 (0.0–2.0) 1 (0–2.0) 0 (0–1.0) 0 (0–0.1) < 0.001
Diabetes mellitus 62 (25.5) 72 (20.7) 28 (15) 20 (10.8) 0.001
COPD 27 (11.1) 29 (8.3) 14 (7.5) 12 (6.5) 0.344
ASA
• I–II 189 (78.1) 274 (79) 159 (86.4) 168 (90.8) 0.001
• III+ 53 (21.9) 73 (21) 25 (13.6) 17 (9.2)
• Missing 2 1 3 1
Surgical technique
• Open 121 (49.8) 154 (44.3) 66 (35.9) 77 (41.6) 0.003
• Laparoscopic 102 (42) 168 (48.3) 105 (57.1) 80 (43.2)
• Conversion 20 (8.2) 26 (7.5) 13 (7.1) 28 (15.1)
• Missing 1 0 3 1
Stoma 69 (38.3) 106 (30.5) 61 (33) 55 (29.7) 0.768
• Missing 0 1 2 1
Length of stay (LOS) 9 (6–14) 7.5 (6–13) 7 (5–10) 7 (5–12) < 0.001
Blood loss (L) 0.159 (0.05–0.40) 1 (0.03–0.40) 0.11 (0.04–0.25) 0.1 (0.02–0.35) 0.065
Operation duration (hours) 2.53 (1.83–3.28) 2.47 (1.83–3.25) 2.5 (2.0–3.2) 2.67 (1.87–3.52) 0.356
Neoadjuvant therapy 57 (23.4) 84 (24.2) 63 (33.7) 57 (30.6) 0.037
Adjuvant chemotherapy 28 (11.6) 60 (17.3) 40 (21.4) 50 (26.9) 0.001
• Missing 3 2 0 0
Tumour characteristics
Tumour stage
• I 82 (33.6) 107 (30.7) 52 (27.8) 64 (34.4) 0.278
• II 82 (33.6) 139 (39.9) 69 (36.9) 56 (30.1)
• III 80 (32.8) 102 (29.3) 66 (35.3) 66 (35.5)
Tumour grade differentiation
• Good 59 (25.5) 89 (26.6) 54 (29.7) 48 (26.4) 0.534
• Moderate 144 (62.3) 214 (64.1) 105 (57.7) 120 (65.9)
• Poor 28 (12.1) 31 (9.3) 23 (12.6) 14 (7.7)
• Missing 13 14 5 4
Angioinvasion
• No 65 (28.8) 94 (28.8) 60 33.9) 57 (32.8) 0.749
• Yes 25 (11.1) 29 (8.9) 15 8.5) 13 (7.5)
• Not reported 136 (60.2) 203 (62.3) 102 57.6) 104 (59.8)
• Missing 18 22 10 12
Location of tumour rectum 64 (26.2) 99 (28.4) 66 (35.3) 67 (36) 0.059
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0.001). Treatment strategies also differed between the quar-
tiles; patients with low SES more often underwent open sur-
gery (p = 0.003) and less often received neoadjuvant and
adjuvant treatment (p = 0.037 and p = 0.001, respectively).
SES and Postoperative Complications
A total of 443 patients (45.9%) suffered at least one postoper-
ative complication. The overall complication rate gradually
decreased from 53.3% in Q1 to 36.0% in Q4 (p < 0.001).
Major complications (i.e. Clavien-Dindo score ≥ 3) occurred
in 170 patients (17.6%), for which a similar gradual decrease
was observed (21.3% in Q1 to 12.4% in Q4; p < 0.001). No
significant differences in readmission and reoperation rates
were observed between the quartiles (Fig. 1).
In univariable logistic regression, GHI was associated with
overall postoperative complications (OR 0.99, 95%CI 0.99 –
0.99, p < 0.001), as was older age (OR 1.02, 95%CI 1.01–
1.04, p < 0.001), rectal cancer (OR 1.56, 95%CI 1.19–2.05, p
= 0.001), and open surgery (OR 0.56, 95% CI 0.44–0.73, p <
0.001). The association between GHI and overall postopera-
tive complications remained significant in the multivariable
model (OR 0.99, 95%CI 0.99–0.998, p = 0.004) (Table 2).
For major postoperative complications, no independent asso-
ciation was found in multivariable analysis (OR 0.99, 95% CI
0.99–1.00, p = 0.103) (Table 3).
SES and Overall Survival
OS increased gradually with increasing socioeconomic status
(Fig. 2). The median OS was only reached in Q1 (88.9
months, 95% CI 79.1–98.7), whereas the median OS was
not reached in any of the other quartiles. Patients in Q1 had
a worse OS compared with patients in Q2 (p = 0.016) and
patients in Q2 had a worse survival compared with patients
in Q3 (p = 0.01). Patients in Q3 and Q4 had a similar survival
(p = 0.918).
In univariable analysis, GHI was associated with OS (HR
0.98, 95% CI 0.98–0.99, p < 0.001). Furthermore, age (HR
1.04, 95% CI 1.02–1.06, p < 0.001), CCI (HR 1.24, 95% CI
1.17–1.32, p < 0.001), tumour stage (HR 1.90, 95%CI 1.42–
2.55, p < 0.001) and tumour grade (HR 1.89, 95%CI 1.29–
2.76, p = 0.001) were associated with OS. In the multivariable
analysis, GHI was not independently associated with OS (HR
0.99, 95%CI 0.99-1.00, p = 0.158), in contrast to age (HR
1.07, 95%CI 1.05–1.08, p < 0.001), CCI (HR 1.17, 95%CI
1.10–1.25, p < 0.001) tumour stage (HR 2.34, 95%CI 1.72–
3.19, p < 0.001) and tumour grade (HR 1.53, 95% CI 1.04–
2.26, p = 0.030) (Table 4).
SES and Cancer-Specific Survival
The median CSS was not reached for any of the quartiles.
Patients in Q1 had a worse CSS compared with patients in
Q2 (p = 0.035). No difference in survival was found between
Q2 and Q3, nor for Q3 and Q4 (p = 0.080 and p = 0.637,
respectively) (Fig. 3).
In the univariable model for CSS, GHI showed a signifi-
cant association (HR 0.98, 95%CI 0.98–0.99, p < 0.001) as
well as age (HR 1.04, 95%CI 1.02–1.06, p < 0.001), CCI (HR
1.14, 95%CI 1.04–1.25, p = 0.006), tumour stage (HR 3.58,
95% CI 2.31–5.56, p < 0.001) and tumour grade (HR 2.62,
95% CI 1.52–4.52, p = 0.001). The association between GHI
and CSS remained statistically significant in the multivariable
model (HR 0.99, 95%CI 0.98–0.99, p = 0.009). Other factors
that were independently associated with CSS were age (HR
1.03, 95%CI 1.01–1.05, p = 0.001) and tumour stage (HR
3.95, 95%CI 2.49–6.28, p < 0.001) (Table 5).
Figure 1 Postoperative
complications per quartile
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Discussion
The results of this study show that lower SES is significantly
associated with worse outcome in patients with stage I–III colo-
rectal cancer undergoing curative surgery. We observed an in-
creased rate of postoperative complications, after correcting for
captured confounding factors. Although SES was not indepen-
dently associated with OS, we observed a significant association
between SES and CSS after correction for other known captured
prognosticators (HR: 0.99 per percentile). This corresponds to a
hazard ratio of 0.80 per quartile incremental SES increase. The
current results should be viewed in the context of theDutch equal
access healthcare system. Therefore, the association between in-
come and postoperative survival that was demonstrated in the
present study cannot be attributed to inequality in healthcare
resources. This is, to our knowledge, the first study to explore
the influence of SES in a prospective cohort of consecutive co-
lorectal cancer patients and stresses the importance of SES as a
prognostic factor in these patients.
As in previous studies, our results indicate that SES is also
associated with short-term outcome [17, 34]. This may partial-
ly be explained by confounding factors associated with both
lower SES and higher postoperative morbidity. At baseline,
diabetes mellitus was more prevalent in patients in the lower
quartiles. This factor, as well as several others, such as liver
disease, is incorporated in the ASA classification. These were
significantly higher in the lower SES quartiles as well.
Patients in the lower SES quartiles more often underwent open
surgery, despite tumour characteristics being similar with
regards to location, stage and pathologic prognostic factors.
Moreover, patients were significantly older in the lower SES
quartiles, and therefore a larger part of these patients may have
been retired the year prior to surgery and have less income.
These differences in treatment, without apparent clinical
explanat ion, mirror those descr ibed in previous
studies.[34–36] Even after correction for known confounding
risk factors including comorbidities, SES was a significant
predictor for postoperative morbidity. These results suggest
that the correlation between SES and postoperative outcomes
is determinant upon factors that are currently not adequately
considered or understood.
In general, long-term results presented in our study are in
line with previous studies, showing impaired survival in pa-
tients with low SES [20, 22, 23, 37]. Several previous studies
have offered explanations for this survival discrepancy in a
setting of equal healthcare access [38–51]. These possible ex-
planations include psychological factors, medication compli-
ance and diet, exercise, air pollution, and even epigenetic fac-
tors [38–51]. Interestingly, in our study, the correlation be-
tween SES and CSS was more outspoken than the correlation
of SES with OS (i.e. all-cause mortality), making some of
these explanations less plausible. In addition, this suggests
that the survival discrepancy between SES quartiles was not
solely attributable to the unequal distribution of age and co-
morbidities between the groups, as these factors have a less
obvious effect on cancer-related outcome. Fowler et al.
Table 2 Univariable and multivariable analyses on overall postoperative complications
Odds ratio Univariable Multivariable
95% confidence interval p value Odds ratio 95% confidence interval p value
Gender–male = reference 0.84 0.65–1.08 0.174 0.79 0.60–1.00 0.086
Age (years) 1.02 1.01–1.04 < 0.001 1.02 1.00–1.03 0.044
Charlson comorbidity 1.09 1.00–1.19 0.051 1.03 0.94–1.00 0.497
Rectal carcinoma 1.56 1.19–2.05 0.001 1.81 1.00–2.00 < 0.001
Surgical technique
Open = reference
0.56 0.44–0.73 < 0.001 0.56 0.42–0.73 < 0.001
Gross household income 0.99 0.99–0.99 < 0.001 0.99 0.99–0.998 0.004
Table 3 Univariable and multivariable analyses on major postoperative complications (Clavien Dindo ≥ 3 )
Univariable Multivariable
Odds ratio 95% confidence interval p value Odds ratio 95% confidence interval p value
Gender–male = reference 0.83 0.60–1.16 0.283 0.85 0.6–1.20 0.354
Age (years) 1.02 1.01–1.04 0.009 1.01 1.00–1.03 0.142
Charlson comorbidity 1.13 1.02–1.25 0.017 1.08 0.97–1.20 0.187
Rectal carcinoma 1.54 1.09–2.17 0.014 1.72 1.19–2.47 0.004
Surgical technique–open procedure = reference 0.47 0.34–0.66 < 0.001 0.47 0.33–0.67 < 0.001
Gross household income 0.99 0.99–0.998 0.009 0.99 0.99–1.00 0.103
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showed that tumour stage and treatment contributed for a great
part towards the difference in 3-month mortality between the
most and least deprived patient groups [52]. Known and rele-
vant tumour characteristics, as earlier described, did not sig-
nificantly differ across SES quartiles. In contrast however,
treatment strategies were different between groups. In addition
to a different surgical approach between the quartiles, fewer
patients of lower SES quartiles received neoadjuvant and ad-
juvant chemotherapy. The inequality of treatment with neoad-
juvant therapy can partially be explained by differences in
proportion of patients with rectal cancer between the SES
quartiles. Neoadjuvant chemotherapy is only registered in pa-
tients with rectal cancer whereas adjuvant chemotherapy is
only offered to patients with colon cancer. However, as in
our study, previous studies show that lower-middle SES and
low-SES patients were less likely to receive chemotherapy in
general [53]. Furthermore, since SES remained significantly
associated with CSS after correction for baseline variables, it
is possible that some of the driving factors of treatment differ-
ences cause additional differences in strategy not captured in
our cohort. Besides differences in the administration of che-
motherapy, compliance with treatment may also play a role.
Prospective studies will be required to elucidate the exact
causal mechanism of this remaining correlation.
GHI was chosen as a surrogate marker for SES in this
study, as it is a proven accurate reflection of SES-related
health disparities [26, 29–31]. It was not adjusted to household
size, as previous studies showed this adjustment did not im-
prove predictability of the associated health disparities [30].
Other reported determinants of SES include the highest
attained level of education, current occupation, parent’s edu-
cation and occupation, and household conditions [34, 36,
54–56]. Unfortunately, no previous studies have compared
the accuracy of these markers in a cohort of (colorectal) cancer
Figure 2 Overall 5 year survival
per socioeconomic income
quartile
Table 4 Univariable and multivariable Cox regression analyses on overall survival
Univariable Multivariable
Hazard ratio 95% confidence interval p value Hazard ratio 95% confidence interval p value
Age 1.04 1.02–1.06 < 0.001 1.07 1.05–1.08 < 0.001
Charlson comorbidity index 1.24 1.17–1.32 < 0.001 1.17 1.10–1.25 < 0.001
Tumour stage I (Ref) - - - - - -
Tumour stage II 1.26 0.93–1.71 0.138 1.20 0.88–1.65 0.253
Tumour stage III 1.90 1.42–2.55 < 0.001 2.34 1.72–3.19 < 0.001
Tumour grade good (Ref) - - - - - -
Tumour grade moderate 0.87 0.65–1.16 0.340 0.81 0.60–1.09 0.167
Tumour grade poor 1.89 1.29–2.76 0.001 1.53 1.04–2.26 0.030
Gross household income 0.98 0.98–0.99 < 0.001 0.99 0.99–1.00 0.158
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patients, which limits their comparability [11–23]. Since GHI
is a valid and readily available metric for all Dutch citizens
registered by an independent organization (Dutch Statistics;
CBS), we believe this marker adequately captures SES for our
purposes. Use of this marker in different populations or dif-
ferent countries would add to the comparability of the plethora
of SES studies currently being conducted.
Some inherent shortcomings of this study should be noted.
First, with regards to patient factors, we were unable to deter-
mine several lifestyle factors of potential importance, due to
the inherent limitations in our database. These include
smoking, diet, and compliance with medication [44, 45, 57].
Even though these factors reportedly do not explain all differ-
ences, we believe correcting for them would have enhanced
our results [30, 58, 59]. An additional drawback in our study
was our inability to comment on exact healthcare
consumption for CRC and comorbidities, limiting our ability
of testing the premise of equal healthcare accessibility.
Variation in SES between the hospitals can have some effect
on the outcome; however, guideline adherence was equal
across the hospitals plus complications and survival outcomes
did not differ between the hospitals.
Finally, ethnicity could be a confounding factor with SES,
and the unfavourable surgical outcome of GHI in this study
might also partially be explained by differences in ethnicity.
However, ethnicity is not reported in the Netherlands, which
limits this study because no analyses can be performed on the
actual relevance of this risk factor [37].
In conclusion, our results show that low SES is associated
with worse outcome in patients undergoing curative surgery
for stage I–III colorectal cancer. Future studies are required to
elucidate the association between SES and survival in cancer
Table 5 Univariable and multivariable Cox regression analysis on cancer specific survival
Univariable Multivariable
Hazard ratio 95% confidence interval p value Hazard ratio 95% confidence interval p value
Age 1.04 1.02–1.06 < 0.001 1.03 1.01–1.05 0.001
Charlson comorbidity index 1.14 1.04–1.25 0.006 1.07 0.96–1.18 0.214
Tumour stage I (Ref) - - - - - -
Tumour stage II 1.33 0.81–2.19 0.262 1.28 0.76–2.16 0.353
Tumour stage III 3.58 2.31–5.56 < 0.001 3.95 2.49–6.28 < 0.001
Tumour grade good (Ref) - - - - - -
Tumour grade moderate 1.19 0.77–1.84 0.430 1.09 0.71–1.69 0.694
Tumour grade pore 2.62 1.52–4.52 0.001 1.84 1.06–3.19 0.031
Gross household income 0.98 0.98–0.99 < 0.001 0.99 0.98–0.997 0.009
Figure 3 Cancer specific survival
per socioeconomic income
quartile
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patients, which suggest that SES encompasses risk factors and
behaviours currently not adequately considered. Such studies
would require additional power and potential explaining fac-
tors and would ideally be able to distinguish between the
effects of patient and treatment related measures.
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